Dose-dependent change in tissue uptake of 17 beta-(16 alpha-[125I]iodo)-estradiol in female rats: application to external imaging of mammary carcinoma.
Recently, many studies have drawn attention to the possibility of imaging estrogen-receptor-positive breast cancer with a high-affinity ligand such as 17 beta-(16 alpha-[125I]iodo)-estradiol (I-E2). We tried to determine the most suitable time and dose for imaging with this compound, using uteri of mature Sprague-Dawley rats. Although the uptake of I-E2 in the target organ (uterus) reached its peak 1 h after subcutaneous injection, the ratio of uptake in the target organ to that in nontarget organs (lung and muscle) peaked at 4 h. We also found that this ratio decreased as the dose increased. The clearest image was available 4 h after the dose meeting the minimum requirement for imaging was administered. An imaging trial of dimethylbenzanthracene (DMBA)-induced mammary carcinoma is also demonstrated.
D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000031:analogs & derivatives* / Q000378:metabolism; D005260:Female; D007457:Iodine Radioisotopes; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000000981:diagnostic imaging*; D009376:Neoplasms, Hormone-Dependent / Q000000981:diagnostic imaging; D011877:Radionuclide Imaging; D051381:Rats; D011919:Rats, Inbred Strains; D014018:Tissue Distribution
D007457:Iodine Radioisotopes; D004958:Estradiol; D015127:9,10-Dimethyl-1,2-benzanthracene; C024871:16 alpha-iodoestradiol